In the SURMOUNT program (SM), treatment with tirzepatide led to a significant and clinically meaningful reduction in body weight (BW) in overweight and obese subjects. In a post-hoc analysis, the effect of tirzepatide treatment on body weight in women was examined according to the stage of menopause.
Autoren
- Jens Dehn
Publikation
- InFo DIABETOLOGIE & ENDOKRINOLOGIE
Related Topics
You May Also Like
- HER2+ metastatic breast cancer
New therapeutic standards with SHR-A 1811
- Angina tonsillaris: clinical management
Conservative therapy or surgery?
- Dermocosmetic for mild to moderate acne
Effects of an anti-pimple cream: randomized split-face study
- Neuro-ophthalmology
Visual Snow Syndrome: From the mysterious disorder to effective treatment options
- Platelet and leukocyte abnormalities
Clonal or reactive causes?
- Gonarthrosis and coxarthrosis: update on conservative treatment
Pain relief, targeted movement and relief
- Idiopathic and progressive pulmonary fibrosis (IPF/PPF)
An instrument for clinical use
- Rosacea - multifaceted and multifactorial